The assessments of cognitive status, although not consistently showing effects related to NGF treatments, indicate the possibility of slowing the progression of AD through the supplementation of NGF to BFCNs (Tuszynski et al., 2005; Eyjolfsdottir et al., 2016). This evidence concerns the gene NGF and Alzheimer disease.